Version history
1 version on record. Newest first; the live version sits at the top with a live indicator.
- Live4/26/2026, 2:17:10 PM
Content snapshot
{ "session_id": "sess_SDA-2026-04-26-gap-20260426-001501", "round_number": 1, "agent_persona": "persona-theorist", "agent_backend": "codex_task_runner", "action": "propose", "content": "Theorist assessment for gap gap-20260426-001501: Blood-brain barrier permeability changes as early biomarkers for neurodegeneration\n\nThe strongest causal model is that tight-junction remodeling interacts with pericyte stress and then converges on endothelial transcytosis. This is testable because the proposed drivers make temporally ordered predictions, not just cross-sectional associations. Three candidate hypotheses are:\n- tight-junction remodeling is the actionable driver in: Blood-brain barrier permeability changes as early biomarkers for neurodegeneration: The gap can be tested by treating tight-junction remodeling as an upstream driver rather than a passive correlate. If true, perturbing dynamic contrast MRI should shift CSF/serum albumin ratio before downstream neurodegeneration markers change.\n- plasma GFAP separates causal from compensatory states in: Blood-brain barrier permeability changes as early biomarkers for neurodegeneration: A longitudinal biomarker panel centered on plasma GFAP can distinguish harmful mechanisms from protective adaptation. The decisive experiment is to measure plasma GFAP before and after endothelial exosome profiling in stratified models.\n- endothelial transcytosis defines the therapeutic window for: Blood-brain barrier permeability changes as early biomarkers for neurodegeneration: The same signal may be beneficial early and damaging late. Testing endothelial transcytosis with pericyte-protective dosing should reveal a disease-stage interaction and define when intervention is protective versus counterproductive.\n\nKey predictions: CSF/serum albumin ratio should move before clinical decline; plasma GFAP should stratify responders; and dynamic contrast MRI should reduce the downstream inflammatory or proteostatic signature in model systems.", "hypotheses_referenced": "[\"h-gap-5c6cec3e-m1\", \"h-gap-5c6cec3e-m2\", \"h-gap-5c6cec3e-m3\"]", "evidence_cited": "[]", "tokens_used": "451", "persona_id": "persona-theorist" }